Cepheid Inc: (NASD: CPHD)

$38.27

-0.25 (-0.65%)

Volume 378,364

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		38.09 - 38.80
	
		52wk Low - High
		28.12 - 46.00
	
		Previous Close
		38.52
	
		Avg. Volume
		471,949
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		2.56 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.20
	
		PE (Forward)
		0.00
	
		Current Year Est.
		0.00
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		99 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            0.00
                        
                            Current Quarter Estimate
                            -0.04
                        
                            Most Accurate Estimate
                            -0.04
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-18-2013
                        
                            EPS Last Year
                            0.08
                        
                            Expected Earnings Growth
                            21.25%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Cepheid, Inc. develops, manufactures and markets microfluidic systems that integrate, automate and accelerate biological testing. Their systems are miniaturized instruments that analyze complex biological samples in a disposable cartridge by combining molecular biology with microfluidic technology that processes small quantities of liquid, typically using components fabricated with computer chip technology.  These systems rapidly perform all of the steps required to analyze complex biological samples.   
Full CPHD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CPHD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.04	0.00	0.00	0.23
Number of Estimates	11	11	13	11
Low Estimate	-0.06	-0.02	-0.05	0.02
High Estimate	0.01	0.01	0.05	NA
Year Ago EPS	0.03	-0.08	-0.04	0.00
EPS Growth	-224.24%	96.59%	94.23%	10,184.85%

More CPHD Estimates

Average Earnings Estimates for CPHD

EPS Growth for CPHD

Industry Analysis

Name	Symbol	Previous Close
CEPHEID INC	CPHD	38.27
NATUS MEDICAL	BABY	14.36
CRYOLIFE INC	CRY	6.34
DELCATH SYS INC	DCTH	0.41
GLOBUS MEDICAL	GMED	15.69
HEARTWARE INTL	HTWR	99.19
MELA SCIENCES	MELA	1.07
OXYSURE SYSTEMS	OXYS	0.90
PACIFIC BIOSCI	PACB	2.42
SUNSHINE HEART	SSH	5.49

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Neutral Rating Restated for Cepheid

May 13, 2013

DexCom Loss Narrower than Est.

May 02, 2013

Huge Earnings Miss By AMED, Guides Low

May 01, 2013

ResMed's Earnings Beat; Revs Lag

Apr 29, 2013

Covidien Expands Shiley Offerings

Apr 19, 2013

FDA Nod for Luminex Offering

Apr 19, 2013

Cepheid Earnings Beat, Retains Outlook

Apr 19, 2013

New Patent for Biolase

Apr 18, 2013

More CPHD Zacks Commentary

Financials

EPS TTM	0.08
Sales	331
Net Income	-14
Price/Earnings	478.38
Price/Book	9.79
Price/Cash Flow	161.29
Price/Sales	7.45

More CPHD Financials

News

WEALTHMAKERS.COM Issues Bullish Research Reports on NICK, PDI, PRGS, ROIAK, SNAK - M2

May 14, 2013

Friday Sector Leaders: Education & Training Services, Television & Radio Stocks - Marketnewsvideo.Com

May 10, 2013

Radio One, Inc. Reports First Quarter Results - Pr Newswire

May 9, 2013

Radio One Sets Date for 1st Quarter 2013 Results Conference Call - Close-Up Media

May 2, 2013

Radio One Sets Date to Announce First Quarter 2013 Results - Close-Up Media

May 2, 2013

Radio One to Host 1Q 2013 Results Conference Call - Close-Up Media

May 2, 2013

Radio One, Inc. Class DCorporate Event Announcement Notice - Wall Street Horizon

Apr 29, 2013

Radio One, Inc. First Quarter 2013 Results Conference Call - Pr Newswire

Apr 29, 2013

See All News Stories on CPHD

Broker Recommendations

Current ABR	1.73
ABR (Last Week)	1.73
# of recs in ABR	15
Average Target Price	40.75
Industry Rank by ABR	114 out of 265
Rank in Industry	10 out of 52

More CPHD Broker Recommendations

Day Low - High	38.09 - 38.80
52wk Low - High	28.12 - 46.00
Previous Close	38.52
Avg. Volume	471,949
Industry	MED INSTRUMENTS
Market Cap	2.56 B
Div - Yield	0.00 - 0.00
Beta	1.20
PE (Forward)	0.00
Current Year Est.	0.00
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	0.00
Current Quarter Estimate	-0.04
Most Accurate Estimate	-0.04
Earnings ESP	0.00%
Next Earnings Report Date	07-18-2013
EPS Last Year	0.08
Expected Earnings Growth	21.25%

Username: Password:

Remember me [?]

Cepheid Inc: (NASD: CPHD)

$38.27

-0.25 (-0.65%)

Volume 378,364

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED INSTRUMENTS

Zacks Commentary

Financials

News

Broker Recommendations